Olema's Spending Climbs With Two Late-Stage Breast Cancer Trials as Data Date Holds
The biotech's third-quarter net loss rose to $73.6M, with $413.8M in cash, as its two palazestrant Phase 3 studies continue recruiting and a first read-out remains scheduled for early 2027.
Olema Pharmaceuticals reported a third-quarter 2026 net loss of $73.6M on 10 November, up from $42.2M a year earlier. The company tied the increase to its two Phase 3 studies of palazestrant in ER+/HER2- metastatic breast cancer, OPERA-01 and OPERA-02, both of which are still enrolling patients.
The company ended the quarter with $413.8M in cash. It did not alter guidance for OPERA-01: top-line data are still expected in the first quarter of 2027. No efficacy results from the Phase 3 programme have been released, and any later regulatory filing would depend on that read-out.
On the management side, Olema has appointed Jason O'Byrne as chief financial officer. No further detail on the appointment was available to us.
Beyond breast cancer, Olema plans to start a Phase 1b/2 trial in the fourth quarter of 2026 combining OP-3136 with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). The start is subject to the company's timetable holding.
The full text of the company's release was not available to us, so further financial detail, such as operating expense breakdowns, cash runway and trial design, is not covered here.
Why it matters
- The Q1 2027 OPERA-01 read-out is the next major value-defining event for palazestrant, and the timeline is unchanged.
- The loss widening reflects the cost of running two concurrent Phase 3 trials; the $413.8M cash balance is the figure to watch against that burn.
- With no efficacy data yet, market-access and commercial teams tracking ER+/HER2- metastatic breast cancer have nothing to benchmark the programme against.
- The planned OP-3136 and darolutamide study in mCRPC would take Olema into prostate cancer, if it starts as planned in Q4 2026.
Company's press release (SEC filing): Olema Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
